Page 22 - Lupin

Lupin, YL Biologics get nod to market rheumatoid arthritis drug in Japan

In February 2018, YL Biologics had announced completion of the global phase III study of their biosimilar Etanercept

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

'Official Action Indicated' means approvals of pending applications or supplements from this site maybe withheld

Latest FDA action is a 'sentimentally negative outcome' for Lupin

The company has slipped to being the seventh-largest pharma company in terms of market cap

Lupin recalls 43,860 ophthalmic solution bottles in US over impurities

The product is being recalled by Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of the company

Delhi HC sets aside govt ban on Lupin FDC, refers matter back to Drug Board

Govt had in September 2018 banned 344 FDC drugs, including Lupin's combo for diabetics, citing lack of therapeutic justification

Lupin registers tepid growth in India revenues, US sales remain subdued

While the actual Dec quarter revenue was much more than estimates, the same was due to higher licensing income

Lupin gets USFDA approval to market hypothyroidism treatment drug

The product is a generic version of AbbVie Inc's Synthroid tablets in the same strengths

Lupin recalls over 23,000 bottles of antibiotic drug for being sub-potent

The drug is manufactured by Novel Laboratories Inc for Baltimore-based Lupin Pharmaceuticals, Inc

Lupin plans expansion, eyes Europe growth via acquisitions and launches

The pharma major acquired a portfolio of central nervous drug system drugs, including NaMuscla, through its acquisition of German drug maker Temmler Pharma in 2015

Lupin: Street waits for progress on new launches, resolution of plants

Growth depends on key regulatory approvals

Lupin ties up with US-based AbbVie for cancer drug, to earn $ 1 billion

The drug maker will earn over $1 billion in fee, milestone payments, royalties from US firm

European court upholds fine against drugmakers Lupin and Unichem

A total fine of 315 million Euros have been upheld on six companies.

Lupin plans expansion, eyes product purchase in chronic and acute therapy

Chronic therapies refer to drugs for ailments which are chronic in nature such as diabetes, hypertension, etc

Lupin shares fall over 4% after company's Q2 net profit dropped 41.5%

The stock dropped 4.13 per cent to end at Rs 852.20 on the BSE. Intra-day, it declined 4.49 per cent to Rs 849

Lupin to develop Brazil as Latin American manufacturing, export hub

Most neighbouring countries recognise the Brazilian drug regulator's approvals

Lupin receives Europe's positive opinion for antimyotonic agent 'NaMuscla'

The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU), the Mumbai-based firm added

Lupin starts strategic review of Japanese arm, targets higher-growth areas

Japanese subsidiaries of Lupin produce treatments in therapeutic areas, including psychiatry and neurology

Lupin's Nagpur facility gets Establishment Inspection Report from US FDA

Shares of Lupin were today trading at Rs 903 per scrip on BSE, down 0.07 per cent from its previous close

Weak US sales take toll on Lupin Q1 performance, stock slides 4.5%

North America sales fall by a quarter, indicating intense pricing pressures

Pharma major Lupin gets UK health regulator's approval for Goa facility

The unit was inspected by United Kingdom's Medicines and Healthcare products Regulatory Agency in March 2018 and there were no critical or major observations cited